Alectinib, Free Base

Alectinib, Free Base
Item number Size Datasheet Manual SDS Delivery time Quantity Price
LC-A-2300_25mg 25 mg -

3 - 15 business days*

83.00€
LC-A-2300_50mg 50 mg -

3 - 15 business days*

97.00€
LC-A-2300_100mg 100 mg -

3 - 15 business days*

128.00€
LC-A-2300_200mg 200 mg -

3 - 15 business days*

177.00€
LC-A-2300_250mg 250 mg -

3 - 15 business days*

200.00€
LC-A-2300_500mg 500 mg -

3 - 15 business days*

304.00€
LC-A-2300_1g 1 g -

3 - 15 business days*

429.00€
LC-A-2300_2g 2 g -

3 - 15 business days*

751.00€
LC-A-2300_5g 5 g -

3 - 15 business days*

1,336.00€
 
Soluble in DMSO.. Alectinib, also known as CH 5424802, is a potent, selective, and orally... more
Product information "Alectinib, Free Base"
Soluble in DMSO.. Alectinib, also known as CH 5424802, is a potent, selective, and orally available ALK inhibitor (IC50 = 1.9 nM) and has weak or no inhibition against 24 other tested protein kinases. It has selective antitumor activity against cancers with ALK gene alterations, including non-small cell lung cancer (NSCLC) cells expressing EML4-ALK fusion and anaplastic large-cell lymphoma (ALCL) cells expressing NPM-ALK fusion in vitro and in vivo. It also blocked ALK L1196M, which corresponds to the gatekeeper mutation giving common resistance to kinase inhibitors, and prevented EML4-ALK L1196M-driven cell growth. Sakamoto H., et al. 'CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.' Cancer Cell 19: 679-690 (2011). Alectinib reduced the tumor size in EML4-ALK-positive xenograft tumors that was not able to regress fully during treatment with crizotinib. Alectinib also inhibited the growth of some EML4-ALK mutant-driven tumors, such as the G1269A model. Kodama T., et al. 'Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.' Cancer Lett. 351: 215-221 (2014). Two ALK mutations, a V1180L gatekeeper mutation from the cell line model and I1171T mutation from a patient, were found to develop resistance to alectinib and to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Katayama R., et al. 'Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.' Clin. Cancer Res. 20: 5686-5696 (2014). This research compound is the free acid form of alectinib, we also offer the HCl salt form of alectinib, please see Cat. No. A-2311, Alectinib, Hydrochloride Salt. The free base form of alectinib is used for some or all alectinib formulations for use in humans.
Keywords: CH 5424802
Supplier: LC Laboratories
Supplier-Nr: A-2300

Properties

Application: Antineoplastic, Anaplastic lymphoma kinase (ALK) inhibitor
MW: 482.62 D
Formula: C30H34N4O2
Purity: >99%
Format: Solid

Database Information

CAS : 1256580-46-7| Find alternatives
KEGG ID : K05119 | Find alternatives

Handling & Safety

Storage: -20°C
Shipping: +20°C (International: +20°C)
Signal Word: Warning
GHS Hazard Pictograms:
H Phrases: H302+H312+H332
P Phrases: P262
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Alectinib, Free Base"
Write a review
or to review a product.
Viewed